Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.
The report details the trend, potential and market size of Hemophilia A and B Recombinant Factor Replacement Therapy market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Hemophilia A and B Recombinant Factor Replacement Therapymarket, defines the market attractiveness level of Hemophilia A and B Recombinant Factor Replacement Therapy market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Hemophilia A and B Recombinant Factor Replacement Therapy industry, describes the types of Hemophilia A and B Recombinant Factor Replacement Therapy market, the applications of major players and the market size, and deeply analyzes the current situation of the global Hemophilia A and B Recombinant Factor Replacement Therapy market and the development prospects and opportunities of Hemophilia A and B Recombinant Factor Replacement Therapy industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Hemophilia A and B Recombinant Factor Replacement Therapy market in Chapter 13.
By Player:
Bayer
Spark therapeutics
Baxalta
Emergent Biosolutions
Biogen
Uniqure
Novo Nordisk
CSL Behring
Pfizer
By Type:
Haemophilia A
Haemophilia B
By End-User:
Hospitals
Clinics
Ambulatory Surgical Centers
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Hemophilia A and B Recombinant Factor Replacement Therapy Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Hemophilia A and B Recombinant Factor Replacement Therapy Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Hemophilia A and B Recombinant Factor Replacement Therapy Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Hemophilia A and B Recombinant Factor Replacement Therapy Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Hemophilia A and B Recombinant Factor Replacement Therapy Market Analysis and Outlook to 2022
-
7.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Consumption (2017-2022)
-
7.2 United States Hemophilia A and B Recombinant Factor Replacement Therapy Consumption (2017-2022)
-
7.3 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Consumption (2017-2022)
-
7.4 China Hemophilia A and B Recombinant Factor Replacement Therapy Consumption (2017-2022)
-
7.5 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Consumption (2017-2022)
-
7.6 India Hemophilia A and B Recombinant Factor Replacement Therapy Consumption (2017-2022)
-
7.7 South Korea Hemophilia A and B Recombinant Factor Replacement Therapy Consumption (2017-2022)
8 Region and Country-wise Hemophilia A and B Recombinant Factor Replacement Therapy Market Analysis and Outlook to 2028
-
8.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast (2022-2028)
-
8.2 United States Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast (2022-2028)
-
8.3 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast (2022-2028)
-
8.4 China Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast (2022-2028)
-
8.5 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast (2022-2028)
-
8.6 India Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast (2022-2028)
-
8.7 South Korea Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast (2022-2028)
9 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Outlook by Types and Applications to 2022
-
9.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Haemophilia A Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Haemophilia B Consumption and Growth Rate (2017-2022)
-
9.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)
10 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Outlook by Types and Applications to 2028
-
10.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Haemophilia A Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Haemophilia B Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)
11 Global Hemophilia A and B Recombinant Factor Replacement Therapy Import and Export Analysis (Top 5 Countries)
-
11.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Hemophilia A and B Recombinant Factor Replacement Therapy Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Competitive Analysis
-
14.1 Bayer
-
14.1.1 Bayer Company Details
-
14.1.2 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
14.2 Spark therapeutics
-
14.2.1 Spark therapeutics Company Details
-
14.2.2 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
14.3 Baxalta
-
14.3.1 Baxalta Company Details
-
14.3.2 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
14.4 Emergent Biosolutions
-
14.4.1 Emergent Biosolutions Company Details
-
14.4.2 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
14.5 Biogen
-
14.5.1 Biogen Company Details
-
14.5.2 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
14.6 Uniqure
-
14.6.1 Uniqure Company Details
-
14.6.2 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
14.7 Novo Nordisk
-
14.7.1 Novo Nordisk Company Details
-
14.7.2 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
14.8 CSL Behring
-
14.8.1 CSL Behring Company Details
-
14.8.2 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
14.9 Pfizer
-
14.9.1 Pfizer Company Details
-
14.9.2 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Hemophilia A and B Recombinant Factor Replacement Therapy
-
Figure Hemophilia A and B Recombinant Factor Replacement Therapy Picture
-
Table Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Hemophilia A and B Recombinant Factor Replacement Therapy Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Hemophilia A and B Recombinant Factor Replacement Therapy Consumption by Country (2017-2022)
-
Figure United States Hemophilia A and B Recombinant Factor Replacement Therapy Consumption and Growth Rate (2017-2022)
-
Table Europe Hemophilia A and B Recombinant Factor Replacement Therapy Consumption and Growth Rate (2017-2022)
-
Figure China Hemophilia A and B Recombinant Factor Replacement Therapy Consumption and Growth Rate (2017-2022)
-
Figure Japan Hemophilia A and B Recombinant Factor Replacement Therapy Consumption and Growth Rate (2017-2022)
-
Figure India Hemophilia A and B Recombinant Factor Replacement Therapy Consumption and Growth Rate (2017-2022)
-
Figure South Korea Hemophilia A and B Recombinant Factor Replacement Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast by Country (2022-2028)
-
Figure United States Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Hemophilia A and B Recombinant Factor Replacement Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Haemophilia A Consumption and Growth Rate (2017-2022)
-
Figure Global Haemophilia B Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)
-
Figure Global Haemophilia A Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Haemophilia B Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Hemophilia A and B Recombinant Factor Replacement Therapy Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Hemophilia A and B Recombinant Factor Replacement Therapy Export by Region (Top 5 Countries) (2017-2028)
-
Table Bayer (Foundation Year, Company Profile and etc.)
-
Table Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
Table Spark therapeutics (Foundation Year, Company Profile and etc.)
-
Table Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
Table Baxalta (Foundation Year, Company Profile and etc.)
-
Table Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
Table Emergent Biosolutions (Foundation Year, Company Profile and etc.)
-
Table Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
Table Biogen (Foundation Year, Company Profile and etc.)
-
Table Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
Table Uniqure (Foundation Year, Company Profile and etc.)
-
Table Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
Table Novo Nordisk (Foundation Year, Company Profile and etc.)
-
Table Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
Table CSL Behring (Foundation Year, Company Profile and etc.)
-
Table CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Product and Service
-
